In a separate 26-week study, LIRA QD was compared to insulin glargine (GLARG) on a background of MET+SFU in patients with T2DM, and the mean ratio of proinsulin-to-C-peptide decreased significantly compared with GLARG therapy (P=0.0019) [114]. The gene discussed is INS; the disease is type 2 diabetes mellitus.